title: Cytomegalovirus (CMV) infections in patients receiving CMV-IgG-hyperimmunoglobulin prophylaxis after bone-marrow transplantation.
abstract: Conditioning therapy with aggressive chemotherapy and irradiation induces a state of transient combined immunodeficiency in bone-marrow transplant recipients. This promotes the occurrence of severe cytomegalovirus (CMV) infections, the most frequent lethal complication after bone-marrow transplantation (BMT) at present. Forty-four BMT recipients received CMV-IgG-hyperimmunoglobulin for CMV prophylaxis intravenously. The efficacy of this prophylaxis and possible risk factors for the occurrence of CMV-induced interstitial pneumonia (IP) were analyzed. Risk factors for the promotion of a CMV-IP were: additional immunosuppressive therapy after BMT, CMV-positive serostatus of the recipient, CMV-seropositive granulocyte transfusion, CMV infection immediately prior to BMT, and HLA-haploidentical BMT. In this study the incidence of graft-versus-host disease was low and was not associated with the incidence of CMV infections. The use of T-cell-depleted grafts did not result in increased CMV infections or IP and may possibly have improved the immunological reconstitution.
authors.affiliation: Einheit für Knochenmarktransplantation, Abteilung Innere Medizin III, Universität Ulm.
authors.forename: T
authors.initials: T
authors.lastname: Schmeiser
authors.forename: W
authors.initials: W
authors.lastname: Heit
authors.forename: R
authors.initials: R
authors.lastname: Arnold
authors.forename: D
authors.initials: D
authors.lastname: Bunjes
authors.forename: M
authors.initials: M
authors.lastname: Wiesneth
authors.forename: B
authors.initials: B
authors.lastname: Hertenstein
authors.forename: W
authors.initials: W
authors.lastname: Hampl
authors.forename: H
authors.initials: H
authors.lastname: Heimpel
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D016026:Bone Marrow Transplantation; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G